Translational relevance
Myeloma is a heterogeneous malignancy with disease in different subgroups of 42 patients driven by abnormalities in multiple genes and/or molecular pathways. 
89
The myeloma clone is thought to be immortalised following the acquisition of a 90 translocation into the immunoglobulin heavy chain locus (t(4;14), t(6;14), t(11;14), Patients carrying the t(4;14), around 15% of myeloma cases at clinical diagnosis (8, 104 9), tend to respond to treatment but relapse early and have a shorter overall survival, 105 though since the use of proteasome inhibition there is evidence that this poor 106 prognosis is ameliorated.
107
The impact of mutation on epigenetic modifiers in myeloma has also been reported, processing, processes for somatic mutation calling and molecular and copy number 160 assessments are described fully elsewhere(13). Where CCF=cancer clonal fraction (proportion of cells containing the mutation),
174
CN=copy number at that site, r=number of reads containing the mutation at that site,
175
R=total number of reads at that site.
176
Further data analysis -Myeloma XI
177
Lists of epigenetic modifiers were curated using database searches and previous 178 publications (Supplementary were mutated in at least 5/463 (>1%) of individuals with frequencies shown in Table   254 1, cancer clonal fraction (CCF), shown in Figure 1 and mutation location annotated Figure 3) .
285
CCF analysis showed HIST1H1E and HIST1H1C mutations to be highly clonal important role in myeloma pathogenesis in these patients.
289
Mutations were also seen in the core histone proteins 2A or absence of any mutation having no effect on progression or survival. (Supplementary Figure 1) . The majority of mutations identified in our Figure 1) .
323
The most frequently mutated demethylase gene was KDM3B, The most frequently mutated gene encoding a histone acetyltransferase (HAT) or 342 deacetylase (HDAC) was the HAT EP300 mutated in 1.3% (6/463) of patients. 
376

Chromatin remodelling complex mutations 377 378
The most frequently mutated genes involved in chromatin remodelling were CHD4 in 379 1.9% (9/463, all missense) of patients and CHD2 in 1.5% (7/463, one frameshift, six (Figure 5B ).
435
The variant allele frequency was compared between the MYXI and UAMS samples DNA modifying enzymes such as DNMT3A, IDH and TET2 predominate.(58, 59) 
515
We found mutations in these genes in myeloma, but at a much lower frequency.
516
Our results highlight possible targeted treatment approaches for patients either at 517 diagnosis or at relapse. For example patients with a KDM6A/UTX mutation or sequenced are indicated by coloured square, pink = missense SNV, yellow = frame shift insertion and 776 green = frame shift deletion. At some sites there was more than one patient with a mutation. The 777 overlying arrows indicate amino acids where the mutations in different protein variants occur at the 778 same equivalent amino acid residues. 779
Figure 3 780
Mutations in histone methyltransferases and demethylases. 781
The methyltransferases and demethylases located at their most commonly recognised site of activity 782 on histone 3 are shown with the percentage of patients harbouring a mutation. Those in bold are 783 mutated in 5 or more patients in the dataset. 784
Figure 4 785
Overall survival is shorter in patients with a KDM6A mutation or deletion and those with a 786 mutation in any DNA modifier. 787 A, Kaplan-Meier curves showing patients with a KDM6A mutation or deletion (n=15, dashed) and 788 those without (n=448, solid 
